177 Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis.

Authors :: Tonnelet D
Edet-Sanson A
Augusto L
Cabourg M
Thureau S
Source :: Clinical nuclear medicine [Clin Nucl Med] 2024 Dec 01; Vol. 49 (12), pp. e668-e669. Date of Electronic Publication: 2024 Oct 14.
Publication Year :: 2024
Abstract: Abstract: Patients with metastatic castration-resistant prostate cancer usually have lymph nodes and bone metastasis. We present a rare case of a 51-year-old patient with metastatic castration-resistant prostate cancer who complained of left truncated sciatica and diffuse bone pain and who was referred for 177 Lu-prostate-specific membrane antigen (PSMA) screening. Pretreatment 68 Ga-PSMA showed left sciatic nerve and multiple bone uptake. Patient underwent stereotactic radiotherapy on the sciatic nerve metastasis (30 Gy in 6 fractions of 5 Gy) before 7.4 GBq of 177 Lu-PSMA infusions. Left truncated sciatica disappeared after stereotactic radiotherapy. No additional toxicity was added to the sciatic nerve from 177 Lu-PSMA after stereotactic radiotherapy.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Subjects :: Humans
Male
Middle Aged
Dipeptides therapeutic use
Ligands
Prostatic Neoplasms radiotherapy
Prostatic Neoplasms pathology
Prostatic Neoplasms diagnostic imaging
Radioisotopes therapeutic use
Prostate-Specific Antigen
Lutetium
Heterocyclic Compounds, 1-Ring therapeutic use
Sciatic Nerve diagnostic imaging

Full Text Access

Tools